Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Scand Cardiovasc J ; 50(4): 243-50, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27146648

ABSTRACT

OBJECTIVES: The Swedish Pulmonary Arterial Hypertension Register (SPAHR) is an open continuous register, including pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients from 2000 and onwards. We hereby launch the first data from SPAHR, defining baseline characteristics and survival of Swedish PAH and CTEPH patients. DESIGN: Incident PAH and CTEPH patients 2008-2014 from all seven Swedish PAH-centres were specifically reviewed. RESULTS: There were 457 PAH (median age: 67 years, 64% female) and 183 CTEPH (median age: 70 years, 50% female) patients, whereof 77 and 81%, respectively, were in functional class III-IV at diagnosis. Systemic hypertension, diabetes, ischaemic heart disease and atrial fibrillation were common comorbidities, particularly in those >65 years. One-, 3- and 5-year survival was 85%, 71% and 59% for PAH patients. Corresponding numbers for CTEPH patients with versus without pulmonary endarterectomy were 96%, 89% and 86% versus 91%, 75% and 69%, respectively. In 2014, the incidence of IPAH/HPAH, associated PAH and CTEPH was 5, 3 and 2 per million inhabitants and year, and the prevalence was 25, 24 and 19 per million inhabitants. CONCLUSION: The majority of the PAH and CTEPH patients were diagnosed at age >65 years, in functional class III-IV, and exhibiting several comorbidities. PAH survival in SPAHR was similar to other registers.


Subject(s)
Familial Primary Pulmonary Hypertension , Hypertension, Pulmonary , Pulmonary Embolism/complications , Aged , Comorbidity , Familial Primary Pulmonary Hypertension/diagnosis , Familial Primary Pulmonary Hypertension/epidemiology , Female , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/epidemiology , Hypertension, Pulmonary/etiology , Incidence , Male , Patient Acuity , Survival Analysis , Sweden/epidemiology
2.
Scand Cardiovasc J ; 48(4): 223-33, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24912571

ABSTRACT

OBJECTIVES: To investigate survival, treatment escalation, effects of first-line single- and first-line combination therapy and prognostic markers in idiopathic- (IPAH), hereditary- (HPAH) and connective tissue disease-associated (CTD-PAH) pulmonary arterial hypertension (PAH). DESIGN: Retrospective analysis of medical journals from PAH patients at Skåne University Hospital 2000-2011. RESULTS: 1-, 2- and 3-year survival was 87%, 67%, and 54%, respectively, for the entire population, but worse (p = 0.003) in CTD-PAH than IPAH/HPAH. After 1, 2 and 3 years, 58%, 41% and 24% of patients starting on single therapy were alive on single therapy. 37.5% of patients on first-line single therapy received escalated treatment at first follow-up. First-line combination therapy more greatly decreased pulmonary vascular resistance index (PVRI, p = 0.017) than first-line single therapy. Only first-line combination therapy improved (p = 0.042) cardiac index (CI). Higher mean right atrial pressure (MRAP, p = 0.018), MRAP/CI (p = 0.021) and WHO functional class (p < 0.001) and lower 6-min walking distance (6MWD, p = 0.001) at baseline, and higher PVRI (p = 0.008) and lower 6MWD (p = 0.004) at follow-up were associated with worse outcome. CONCLUSIONS: We confirm improved survival with PAH-targeted therapies. Survival is still poor and early treatment escalation frequently needed. First-line combination therapy may more potently improve haemodynamics. MRAP/CI may represent a new prognostic marker in PAH.


Subject(s)
Antihypertensive Agents/therapeutic use , Arterial Pressure/drug effects , Hypertension, Pulmonary/drug therapy , Pulmonary Artery/drug effects , Adult , Aged , Atrial Function, Right/drug effects , Atrial Pressure/drug effects , Drug Therapy, Combination , Exercise Tolerance/drug effects , Familial Primary Pulmonary Hypertension/drug therapy , Familial Primary Pulmonary Hypertension/physiopathology , Female , Genetic Predisposition to Disease , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/genetics , Hypertension, Pulmonary/mortality , Hypertension, Pulmonary/physiopathology , Kaplan-Meier Estimate , Male , Middle Aged , Proportional Hazards Models , Pulmonary Artery/physiopathology , Recovery of Function , Retrospective Studies , Sweden , Time Factors , Treatment Outcome , Vascular Resistance/drug effects
3.
Tex Dent J ; 130(4): 291-7, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23767158

ABSTRACT

OBJECTIVES: This study aimed to examine feasibility of testing and frequency of abnormal plasma glucose among dental patients in The Dental Practice-Based Research Network. METHODS: Eligible dental patients were > or = 19 years old and had at least 1 American Diabetes Association-defined risk factor for diabetes mellitus or an existing diagnosis of diabetes or pre-diabetes. Random (fasting not required) plasma glucose was measured in standardized fashion using a commercial glucometer. Readings <70 or >300 mg/dl triggered re-testing. Patients with glucose > or = 126 mg/dl were referred for medical follow-up. RESULTS: Of 498 subjects in 28 dental practices, 491 (98%) consented and 418 (85.1%) qualified for testing. Fifty-one patients (12.2%) had diabetes; 24 (5.7%) had pre-diabetes. Glucose ranged from 50 to 465 mg/dl. One-hundred-twenty-nine subjects (31%) had readings outside the normal range; of these, 28 (6.7%) had readings < 80 mg/dl and 101 (24.2%) had readings > or = 126 mg/dl; in 9 patients (7 with diabetes), glucose was > 200 mg/dl. CONCLUSIONS: A significant proportion of patients tested had abnormal blood glucose. Routine glucose testing in dental practice of populations at risk or diagnosed with diabetes may be beneficial and community dental practices hold promise as settings for diabetes and pre-diabetes screening and monitoring. CLINICAL RELEVANCE: Results suggest that implementation of glucose measurement in dental practice may provide important clinical and health information for both patients and practitioners.

4.
Clin Oral Investig ; 17(5): 1383-8, 2013 Jun.
Article in English | MEDLINE | ID: mdl-22903529

ABSTRACT

OBJECTIVES: This study aimed to examine feasibility of testing and frequency of abnormal plasma glucose among dental patients in The Dental Practice-Based Research Network. METHODS: Eligible dental patients were ≥19 years old and had at least one American Diabetes Association-defined risk factor for diabetes mellitus or an existing diagnosis of diabetes or pre-diabetes. Random (fasting not required) plasma glucose was measured in standardized fashion using a commercial glucometer. Readings <70 or >300 mg/dl triggered re-testing. Patients with glucose ≥126 mg/dl were referred for medical follow-up. RESULTS: Of 498 subjects in 28 dental practices, 491 (98 %) consented and 418 (85.1 %) qualified for testing. Fifty-one patients (12.2 %) had diabetes; 24 (5.7 %) had pre-diabetes. Glucose ranged from 50 to 465 mg/dl. One hundred twenty-nine subjects (31 %) had readings outside the normal range; of these, 28 (6.7 %) had readings <80 mg/dl and 101 (24.2 %) had readings ≥126 mg/dl; in nine patients (seven with diabetes), glucose was >200 mg/dl. CONCLUSIONS: A significant proportion of patients tested had abnormal blood glucose. Routine glucose testing in dental practice of populations at risk or diagnosed with diabetes may be beneficial and community dental practices hold promise as settings for diabetes and pre-diabetes screening and monitoring. CLINICAL RELEVANCE: Results suggest that implementation of glucose measurement in dental practice may provide important clinical and health information for both patients and practitioners.


Subject(s)
Blood Glucose/analysis , Community-Based Participatory Research , Dental Health Services , Diabetes Mellitus/diagnosis , Diabetes Mellitus/epidemiology , Hyperglycemia/diagnosis , Adult , Aged , Analysis of Variance , Chi-Square Distribution , Community Dentistry , Diabetes Mellitus/blood , Feasibility Studies , Female , Humans , Hyperglycemia/epidemiology , Logistic Models , Male , Mass Screening , Middle Aged , Prediabetic State/blood , Sweden/epidemiology , United States/epidemiology , Young Adult
5.
Evid Based Spine Care J ; 3(3): 13-20, 2012 Aug.
Article in English | MEDLINE | ID: mdl-23531493

ABSTRACT

STUDY DESIGN: Prospective case series. OBJECTIVE: To evaluate the effect of three repetitive transforaminal steroid injections in a large series of selected patients with cervical radiculopathy caused by spondylosis. METHODS: Consecutively, 140 patients with long-lasting medical history, clinical findings, and MRI indicating a cervical nerve root origin based on degenerative disease and a positive selective transforaminal diagnostic nerve root blocks with local anesthetics resulting in at least 50% temporary arm pain reduction were included. Before treatment started, patients underwent a clinical examination by a neurosurgeon. All patients were followed-up and evaluated by one physiotherapist at the neurosurgery outpatient clinic. A designed outcome questionnaire including Neck Disability Index (NDI), Symptoms Frequency Index, and Visual Analog Scale for pain intensity were used. A series of three transforaminal steroid injections, with 3 weeks in between, were performed by a neuroradiologist using image intensifier guidance in an x-ray suite. At 12-14 weeks after the first injection, follow-up was performed. Criteria for positive response to the treatment was >50% radicular arm pain reduction. Except for occasional painkillers, no other treatment was given to the patients. RESULTS: Positive response to the treatment was achieved in 49% (n = 69) with a significant difference in NDI and pain intensity between responders and nonresponders. CONCLUSIONS: Repetitive transforaminal steroid injections may reduce symptoms (frequency, intensity, and fewer limitations of daily living activities) of radiculopathy in patients with degenerative disease in the cervical spine at a short time follow-up. [Table: see text].

SELECTION OF CITATIONS
SEARCH DETAIL
...